Intuitive Surgical (NASDAQ: ISRG) saw its shares surge 16% on Wednesday, following a stellar third-quarter earnings report that handily topped analyst estimates and featured an upward revision to the company’s procedure growth forecast, signaling strong future demand for its da Vinci surgical systems.
The surgical robotics leader reported after Tuesday’s market close a significant earnings beat. Q3 revenue climbed 23% year-over-year to $2.51 billion, surpassing the $2.4 billion consensus. Adjusted earnings came in at $867 million, or $2.40 per diluted share, a substantial jump from the $669 million, or $1.84 per share, reported a year ago and well above the $1.98 per share analysts had forecast.
The optimism extended beyond the quarterly beat. The company raised its full-year 2025 procedure growth forecast for its da Vinci systems to a range of 17% to 17.5%, up from its prior outlook of 15.5% to 17%. This guidance upgrade points to accelerating adoption of robotic-assisted surgery in hospitals worldwide.
Wall Street analysts responded swiftly. Truist Securities lifted its price target on the stock to $620 from $525, while RBC Capital bumped its target to $625 from $615. Both new targets imply an upside potential of more than 16% from current levels.
Despite trading at a premium valuation of approximately 48 times forward earnings, the company’s growth narrative remains compelling. Intuitive Surgical continues to rapidly expand its installed base of systems, which grew 14% year-over-year in the second quarter of 2025. This expansion fuels a high-margin, recurring revenue stream; parts and services, which accounted for roughly 75% of total revenue, grew as more procedures were performed on the expanding base of machines.
The recent pullback of about 25% from its 52-week high, while notable, is not uncommon for the volatile growth stock. Valuation metrics, while rich on an absolute basis, are currently below their five-year averages, suggesting a relative discount to its own history. Analyst sentiment remains strongly positive, with 21 of the 32 analysts covering the stock rating it a Buy or Strong Buy.
As a pure-play growth company that does not pay a dividend, Intuitive Surgical’s investment thesis hinges on its dominant market position, the global demographic tailwind of an aging population, and the ongoing expansion of its high-margin, annuity-like revenue base. The blockbuster Q3 update powerfully reinforced this narrative.
